SCYNEXIS

NASDAQ SCYX
$1.97 0.0000 0.0000%
Today share price
Vereinigte Staaten von Amerika
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Показатель: 42 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

95.67M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

73.74M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

2.23
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

48.57M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

-11.66 %

Upcoming events SCYNEXIS

All events
No upcoming events scheduled

Stock chart SCYNEXIS

Stock analysis SCYNEXIS

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

Mehr
0.94 8.79
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

Mehr
1.31 25.38
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

Mehr
0.99 4.40
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

Mehr
-0.29 0.50
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

Mehr
136.74 9.54

Price change SCYNEXIS per year

4.25$ 10.25$
Min Max

Summary analysis SCYNEXIS

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure SCYNEXIS

Revenue and net income SCYNEXIS

All parameters

Stock news SCYNEXIS

All news

Scynexis Shares Fall More Than 30% After Brexafemme Recall >SCYX

Scynexis Shares Fall More Than 30% After Brexafemme Recall >SCYX

Scynexis Shares Slide Premarket on Brexafemme Recall, Study Hold >SCYX

Scynexis Shares Slide Premarket on Brexafemme Recall, Study Hold >SCYX

Scynexis Shares Jump 60% After Licensing Deal With GSK

Scynexis Shares Jump 60% After Licensing Deal With GSK

Anti-Fungal Maker Scynexis Stock Soars on GSK Deal

Scynexis Out-Licensing Brexafemme, Cutting Jobs, Names David Angulo CEO

Scynexis Out-Licensing Brexafemme, Cutting Jobs, Names David Angulo CEO

Scynexis Sees Positive Results From Trials for Ibrexafungerp

Scynexis Sees Positive Results From Trials for Ibrexafungerp

Scynexis Submits Supplemental NDA for Yeast-Infection Treatment

Scynexis Submits Supplemental NDA for Yeast-Infection Treatment

Scynexis Shares Fall Sharply After Follow-On Offering, Trial Data

Scynexis Shares Fall Sharply After Follow-On Offering, Trial Data

Scynexis Shares Down 8.9%, Co. Launches Public Offering of Stock

Scynexis Shares Down 8.9%, Co. Launches Public Offering of Stock

Scynexis Reports Encouraging Results From Trial for Oral Ibrexafungerp

Scynexis Reports Encouraging Results From Trial for Oral Ibrexafungerp

SCYNEXIS Shares Up After Getting EU Orphan Designation for Ibrexafungerp

About company SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Address:
1 Evertrust Plaza, Jersey City, NJ, United States, 07302-6548
Company name: SCYNEXIS
Issuer ticker: SCYX
ISIN: US8112922005
Country: Vereinigte Staaten von Amerika
Exchange: NASDAQ
Currency: $
IPO date: 2014-05-02
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.scynexis.com

On which stock exchange are SCYNEXIS (SCYX) stocks traded?

SCYNEXIS (SCYX) stocks are traded on NASDAQ.

What is the ticker of SCYNEXIS stocks (SCYX)?

The stock ticker of SCYNEXIS’s stocks or in other words, the code is SCYX. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does SCYNEXIS (SCYX) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, SCYNEXIS (SCYX) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are SCYNEXIS (SCYX) stocks traded?

SCYNEXIS (SCYX) stocks are traded on the NASDAQ exchange in dollars.

What is the price of SCYNEXIS (SCYX) stocks today?

The current price of SCYNEXIS stocks on 15.05.2024 is 1.97 dollars. per share.

What is the dynamics of SCYNEXIS (SCYX) stocks from the beginning of the year?

SCYNEXIS (SCYX) quotes have increased by -10.86% from the beginning of the year up to 1.97 dollars. per 1 stocks.

How much did SCYNEXIS (SCYX) stocks increase in мае 2024?

This month SCYNEXIS (SCYX) quotes have increased by 14.53% to 1.97 dollars. per share.

How much are SCYNEXIS (SCYX) stocks worth?

Today, on October, 15.05.2024 SCYNEXIS’s (SCYX) stocks cost 1.97 dollars..

What is the market capitalization of SCYNEXIS (SCYX)?

Capitalization is the market value of SCYNEXIS (SCYX) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 15.05.2024, the market capitalization of SCYNEXIS (SCYX) is estimated at about 95673150 dollars.